Gisadenafil besylate
Tocris Bioscience, part of Bio-Techne | Catalog # 4165
Potent PDE5 inhibitor; orally bioavailable
Key Product Details
Description
Potent PDE5 inhibitor; orally bioavailable
Alternative Names
UK 369003
Product Description
Gisadenafil besylate is a potent PDE5 inhibitor (IC50 = 1.23 nM). Shows >100-fold selectivity for PDE5 over PDE6. Orally bioavailable.Licensing Information
Sold for research purposes under agreement from Pfizer Inc.Product Specifications
Molecular Weight
677.79
Formula
C23H33N7O5S.C6H6O3S
Storage
Desiccate at RT
Purity
≥98% (HPLC)
Chemical Name
5-[2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyrazolo[4,3-d]pyrimidin-7-one benzenesulfonate
CAS Number
334827-98-4
PubChem ID
23449797
InChI Key
STFRDYSZKVPPQF-UHFFFAOYSA-N
SMILES
O=S(C1=CN=C(OCC)C(C3=NC(C2=NN(CCOC)C(CC)=C2N3)=O)=C1)(N4CCN(CC)CC4)=O.O=S(C5=CC=CC=C5)(O)=O
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 6.78 | 10 | |
| DMSO | 67.78 | 100 |
Preparing Stock Solutions
for Gisadenafil besylate
The following data is based on the product molecular weight 677.79
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.48 mL | 7.38 mL | 14.75 mL |
| 5 mM | 0.30 mL | 1.48 mL | 2.95 mL |
| 10 mM | 0.15 mL | 0.74 mL | 1.48 mL |
| 50 mM | 0.03 mL | 0.15 mL | 0.30 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Rawson The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. Bioorg.Med.Chem. 2012 PMID: 22100260
- Hashim and Abrams Emerging drugs for the treatment of benign prostatic obstruction. Exp.Opin.Invest.Drugs 2010 PMID: 20446824
Product Specific Notices for Gisadenafil besylate
For research use only
Loading...
Loading...